contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


virogates-capital-raise-of-dkk-82-million-and-issue-of-1289510-new-shares-have-been-registered

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Virogates er aktiv inden for medicinsk teknologi. I dag udføres forretningsdrift inden for forskning og udvikling af biomarkører og diagnostiske instrumenter til sundhedsindustrien. Produkterne sælges under forskellige mærker og bruges til identifikation, analyse og videre behandling af sygdomme, hovedsageligt hjerte -kar -sygdomme, kræft og neurologiske sygdomme. Virksomheden blev etableret i 2001 og har sit hovedkontor med beliggenhed i Birkerød.

Virogates

Company Announcement no. 10/2024 (November 11, 2024)BIRKERØD, DENMARK – ViroGates A/S (“ViroGates” or the “Company”), a medical diagnostics company developing blood tests that can predict disease...

<div class="mfn-header mfn-header-denmark">Company Announcement no. 10/2024 (November 11, 2024)</div><div class="mfn-body">BIRKERØD, DENMARK – ViroGates A/S (“ViroGates” or the “Company”), a medical diagnostics company developing blood tests that can predict disease risk by measuring levels of stable chronic inflammation in individuals, announces that the capital raise of approximately DKK 8.2 million in relation to the directed emission to suPAR Remedy LLC has been completed. The issue of 1,289,510 new shares at a price of DKK 6.34 per share, resulting in a total subscription price of 8,179,224 DKK, has been registered with the Danish Business Authority.&nbsp;Prior to the increase, the Company’s share capital amounted to DKK 6,447,554, consisting of 6,447,554 shares of nominally DKK 1 each. After the nominal increase of DKK 1,289,510, the Company’s share capital now amounts to DKK 7,737,064, consisting of 7,737,064 shares of nominally DKK 1 each.&nbsp;The change in share capital is reflected in the Company’s articles of association available on the Company’s website.&nbsp;Further information regarding the directed emission to suPAR Remedy LLC can be found in Company Announcement no. 8 from October 14, 2024.For further information, please contact:&nbsp; ViroGates A/S:&nbsp; CEO, Jakob Knudsen&nbsp; Tel. (+45) 2226 1355, email: <a rel="noopener" href="mailto:jk@virogates.com">jk@virogates.com</a>&nbsp; &nbsp; Certified Advisor:&nbsp; Västra Hamnen Corporate Finance&nbsp; Per Lönn&nbsp; Tel. (+46) 40 200 250, email: <a rel="noopener" href="mailto:per.lonn@vhcorp.se">ca@vhcorp.se</a>&nbsp; &nbsp; About ViroGates&nbsp; ViroGates A/S is an international medical technology company developing blood tests for the measurement of chronic inflammation in health clinics and to improve patient care in hospitals. ViroGates markets its blood test products under the suPARnostic® brand.&nbsp; &nbsp; The company was founded in 2000. Headquartered in Denmark, ViroGates’ sales force covers Spain, France, and Benelux, while distributors serve other markets. ViroGates’ shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit <a rel="noopener" href="http://www.virogates.com/">www.virogates.com</a>.&nbsp;</div><div class="mfn-footer mfn-attachment mfn-attachment-general">Attachments <a rel="noopener" href="https://storage.mfn.se/89bd7672-38ee-4cca-8615-80fc03a1760f/virogates-capital-raise-of-dkk-8-2-million-and-issue-of-1-289-510-new-shares-have-been-registered.pdf" class="mfn-generated mfn-primary">ViroGates’ capital raise of DKK 8.2 million and issue of 1,289,510 new shares have been registered</a></div>

ViroGates’ capital raise of DKK 8.2 million and issue of 1,289,510 new shares have been registered